Management of chemotherapy in hemodialysis patients

DOI Web Site 25 References

Bibliographic Information

Other Title
  • 担癌透析患者に対する化学療法
  • 担癌透析患者に対する化学療法 : 3例の治療経験をふまえて
  • タンガン トウセキ カンジャ ニ タイスル カガク リョウホウ : 3レイ ノ チリョウ ケイケン オ フマエテ
  • : 3 cases in our institution
  • : 3例の治療経験をふまえて

Search this article

Abstract

Recent advances in hemodialysis for patients with renal insufficiency have resulted in a longer survival. Consequently, they have an equal or increased risk of suffering from various neoplastic diseases. Some previous reports have indicated the safety and efficacy of chemotherapy in such patients; however, evidence is still lacking. We experienced the management of chemotherapy in 3 hemodialysis patients. Case1, primary macroglobulinemia: A 63-year-old man underwent systemic chemotherapy using rituximab, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), and bortezomib, but disease progression was rapid. He died of the disease 4 months after the start of chemotherapy. Case2, advanced ovarian cancer:A 52-year-old female underwent systemic chemotherapy using paclitaxel and carboplatin, and she achieved a partial response (PR) after receiving 2 courses of chemotherapy. However, she could not continue the chemotherapy because of pneumonia and infectious bedsores. She died of the disease 6 months after the start of chemotherapy. Case3, bilateral external acoustic meatus cancer:A 73-year-old man underwent chemoradiotherapy using 5FU, carboplatin, and external beam radiotherapy (total: 70Gy), but the disease progressed rapidly. He died of the disease 6 months after the start of chemoradiotherapy. Although further studies are needed, standard cancer chemotherapy should be established for patients on hemodialysis.

Journal

References(25)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top